Biggest News Aggregation in the World
📰 Mark Shearman News

Page 2 - Mark Shearman News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Mark Shearman. Real-time updates on events, politics, business and more.

Editas Medicine Announces First Quarter 2021 Results and

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making ...
City Of United Kingdom United States Marks Shearman Mark Shearman Jamesc Mullen

Editas Medicine Announces First Quarter 2021 Results and Update

Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 20...
City Of United Kingdom United States Marks Shearman Mark Shearman Cristi Barnett

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript

Operator Good day and thank you for standing by. Welcome to the Q1 2021 Editas Medicine Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] I would now like to hand the conference over to your first speaker today, Ron Moldaver, Investor Relations. Please go ahead. Ron Moldaver -- Investor Relations Thank you, Julian. Good morning, everyone, and welcome to our first quarter 2021 conference call. Earlier this morning, we issued a press rele...
United States Cory Kasimov Raymond James Gena Wang Ron Moldaver Steve Seedhouse
Source: fool.com

What Really Mattered With Editas Medicine's Q1 Update

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Editas Medicine (NASDAQ:EDIT) entered 2021 with tremendous momentum. Thats definitely not the case anymore: Its shares are down more than 60% from their highs set in January. T...
Charles Albright Madhu Kuma Mark Shearman Cynthia Collins James Mullen Goldman Sachs
Source: fool.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science